Evofem Biosciences, INC. (EVFM) — SEC Filings

Q: What are the key financial highlights for Evofem Biosciences, INC.?

Key financial highlights for Evofem Biosciences, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Evofem Biosciences, INC.?

Key executives at Evofem Biosciences, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Evofem Biosciences, INC. stock?

Risk factors for Evofem Biosciences, INC. (EVFM) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Evofem Biosciences, INC.?

Forward-looking statements and predictions from Evofem Biosciences, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Evofem Biosciences, INC.. Recent 8-K filing on Nov 26, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Evofem Biosciences, INC. on SEC EDGAR

Overview

Evofem Biosciences, INC. (EVFM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Evofem Biosciences, Inc. reported a net loss of $1.569 million for the three months ended September 30, 2025, an improvement from a net loss of $2.365 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $2.397 million, significantly better than the $5.8

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Evofem Biosciences, INC. is neutral.

Filing Type Overview

Evofem Biosciences, INC. (EVFM) has filed 30 8-K, 6 10-Q, 1 DEF 14A, 2 DEFA14A, 1 10-K/A, 2 10-K, 1 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (44)

8-K Filing — 8-K · Nov 26, 2025
Evofem Narrows Q3 Loss Amidst Sales Dip, Royalty Gain Boosts Bottom Line — 10-Q · Nov 13, 2025 Risk: high
Evofem Biosciences, Inc. reported a net loss of $1.569 million for the three months ended September 30, 2025, an improvement from a net loss of $2.365 million i
Evofem Eyes Nasdaq Re-listing, Reverse Split Amidst Product Growth Push — DEF 14A · Oct 29, 2025 Risk: high
Evofem Biosciences, Inc. (EVFM) is strategically focused on increasing net product sales of PHEXX and SOLOSEC, expecting a continuation of its four consecutive
Evofem Biosciences Files 8-K: Agreement Termination & Shareholder Vote — 8-K · Oct 20, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on October 20, 2025, reporting the termination of a material definitive agreement and the submission of matters to a vote
Evofem Biosciences Enters Material Definitive Agreement — 8-K · Oct 17, 2025 Risk: medium
Evofem Biosciences, Inc. announced on October 13, 2025, that it has entered into a material definitive agreement. The company, formerly known as Neothetics, Inc
Evofem Biosciences Changes Special Meeting Date — DEFA14A · Sep 19, 2025 Risk: low
Evofem Biosciences, Inc. is filing definitive additional proxy materials to announce a change in the date of its Special Meeting of Stockholders. The original f
Evofem Biosciences Merger Vote Approaching — DEFA14A · Sep 9, 2025 Risk: medium
Evofem Biosciences, Inc. is holding a special stockholder meeting to vote on its merger with Aditxt. The company anticipates approval of this merger, which is a
Evofem Biosciences Files 8-K on Material Agreement — 8-K · Aug 26, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on August 26, 2025, reporting a material definitive agreement entered into on August 22, 2025. The filing also covers modi
Evofem Narrows Losses Amidst Sales Dip, Going Concern Looms — 10-Q · Aug 14, 2025 Risk: high
Evofem Biosciences, Inc. reported a net loss of $828,000 for the six months ended June 30, 2025, a significant improvement from the $3.458 million net loss in t
Evofem Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 2, 2025 Risk: medium
Evofem Biosciences, Inc. announced on June 26, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of eq
Evofem Biosciences Enters Material Definitive Agreement — 8-K · May 22, 2025 Risk: medium
Evofem Biosciences, Inc. announced on May 19, 2025, that it has entered into a material definitive agreement. The filing does not provide specific details about
Evofem Biosciences Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
Evofem Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first qua
Evofem Biosciences Files 8-K for Material Agreement — 8-K · May 8, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on May 8, 2025, reporting an entry into a material definitive agreement and financial statements. The filing date indicate
Evofem Biosciences Reports Material Agreement — 8-K · Apr 14, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on April 14, 2025, reporting a material definitive agreement entered into on April 8, 2025. The filing also includes finan
Evofem Biosciences Reports Material Agreement — 8-K · Apr 3, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on April 3, 2025, reporting a material definitive agreement entered into on March 28, 2025. The filing also includes finan
Evofem Biosciences Files 2024 Annual Report Amendment — 10-K/A · Mar 28, 2025 Risk: medium
Evofem Biosciences, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Neothetics
Evofem Biosciences Enters Material Definitive Agreement — 8-K · Mar 26, 2025 Risk: medium
Evofem Biosciences, Inc. announced on March 20, 2025, that it entered into a material definitive agreement. The company, formerly known as Neothetics, Inc., is
Evofem Biosciences Files 2024 10-K — 10-K · Mar 24, 2025 Risk: medium
Evofem Biosciences, Inc. filed its 2024 10-K on March 24, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, f
Evofem Biosciences Faces Delisting Concerns — 8-K · Jan 10, 2025 Risk: high
Evofem Biosciences, Inc. filed an 8-K on January 10, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event re
Evofem Biosciences Changes Principal Executive Offices — 8-K · Dec 23, 2024 Risk: low
On December 23, 2024, Evofem Biosciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 7770 Regents R
Evofem Biosciences Enters Material Definitive Agreement — 8-K · Nov 25, 2024 Risk: medium
Evofem Biosciences, Inc. announced on November 19, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Neothetics, Inc.,
Evofem Biosciences Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
Evofem Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter of 2024, detailin
Evofem Biosciences Enters Material Definitive Agreement — 8-K · Nov 6, 2024 Risk: medium
Evofem Biosciences, Inc. announced on October 31, 2024, the entry into a Material Definitive Agreement. The company, formerly known as Neothetics, Inc., is inco
Evofem Terminates Phexxi License Deal with 03 Life Sciences — 8-K · Oct 31, 2024 Risk: high
Evofem Biosciences, Inc. announced on October 27, 2024, the termination of its exclusive license agreement with 03 Life Sciences for the commercialization of Ph
Evofem Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 28, 2024 Risk: medium
Evofem Biosciences, Inc. announced on October 28, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of
Evofem Biosciences Files 8-K with Material Agreements & Equity Sales — 8-K · Oct 3, 2024 Risk: medium
Evofem Biosciences, Inc. announced on September 27, 2024, that it entered into a Material Definitive Agreement. The company also reported triggering events that
Evofem Biosciences Enters Material Agreement, Files 8-K — 8-K · Sep 25, 2024 Risk: medium
Evofem Biosciences, Inc. announced on September 20, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales
Evofem Biosciences Enters Material Definitive Agreement — 8-K · Sep 6, 2024 Risk: medium
Evofem Biosciences, Inc. announced on September 6, 2024, that it has entered into a Material Definitive Agreement. The filing does not provide specific details
Evofem Biosciences to be Delisted from Nasdaq — 8-K · Aug 30, 2024 Risk: high
Evofem Biosciences, Inc. received a notice on August 28, 2024, indicating it failed to meet the continued listing standards of The Nasdaq Stock Market LLC. The
Evofem Biosciences Enters Material Definitive Agreement — 8-K · Aug 20, 2024 Risk: medium
Evofem Biosciences, Inc. announced on August 16, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details on the
Evofem Biosciences Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
Evofem Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope
Evofem Biosciences Secures $10M Loan — 8-K · Jul 23, 2024 Risk: medium
On July 17, 2024, Evofem Biosciences, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an affiliate of its largest stockhol
Evofem Biosciences Files 8-K — 8-K · Jul 18, 2024 Risk: low
Evofem Biosciences, Inc. filed an 8-K on July 18, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits as of July 17, 2024. The comp
Evofem Biosciences Holds Annual Meeting, Approves Key Proposals — 8-K · Jun 26, 2024 Risk: low
On June 20, 2024, Evofem Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockhol
Evofem Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk:
Evofem Biosciences, Inc. (EVFM) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Evofem Biosciences, Inc. filed a 10-Q report for the period ending
Evofem Biosciences Terminates Adare Pharma Deal, Enters New Agreement — 8-K · May 2, 2024 Risk: medium
Evofem Biosciences, Inc. announced on April 26, 2024, the termination of its Material Definitive Agreement with Adare Pharma Solutions. The company also entered
Evofem Biosciences Files Current Report — 8-K · Mar 28, 2024 Risk: low
Evofem Biosciences, Inc. filed an 8-K on March 28, 2024, reporting an event on March 27, 2024. The filing is a current report under Regulation FD and includes f
Evofem Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024 Risk:
Evofem Biosciences, Inc. (EVFM) filed a Annual Report (10-K) with the SEC on March 27, 2024. Evofem Biosciences, Inc. filed its annual report on Form 10-K for t
Evofem Biosciences Enters Material Definitive Agreement — 8-K · Mar 6, 2024 Risk: medium
Evofem Biosciences, Inc. announced on February 29, 2024, that it entered into a Material Definitive Agreement. The company, previously known as Neothetics, Inc.
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
Evofem Biosciences Updates Principal Executive Office Address — 8-K · Feb 1, 2024
Evofem Biosciences, Inc. filed an 8-K on February 1, 2024, to update its principal executive offices to 7770 Regents Road, Suite 113-618, San Diego, CA 92122. T
Evofem Biosciences Reports Undisclosed Material Agreement — 8-K · Jan 31, 2024
Evofem Biosciences, Inc. filed an 8-K on January 31, 2024, to report an "Entry into a Material Definitive Agreement" that occurred on January 30, 2024. While th
Evofem Biosciences Amends 8-K/A for Address Correction — 8-K/A · Jan 25, 2024
Evofem Biosciences, Inc. filed an amended 8-K/A on January 25, 2024, to correct its principal executive office address. The original 8-K filed on December 21, 2
Evofem Biosciences Reports Material Definitive Agreement; Details Undisclosed — 8-K · Jan 11, 2024
Evofem Biosciences, Inc. filed an 8-K on January 11, 2024, reporting an "Entry into a Material Definitive Agreement" on January 8, 2024. While the filing indica

Risk Profile

Risk Assessment: Of EVFM's 36 recent filings, 6 were flagged as high-risk, 25 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Evofem Biosciences, INC.'s most recent 10-Q filing (Nov 13, 2025):

Revenue: $4.952M
Net Income: -$1.569M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $7.918M
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

Saundra Pelletier
Ivy Zhang

Industry Context

Evofem operates in the highly competitive women's health and contraceptive market. The market is characterized by established pharmaceutical companies and a growing demand for innovative and convenient solutions. Key trends include a focus on non-hormonal options and direct-to-consumer marketing strategies.

Top Tags

material-agreement (13) · financials (7) · material-definitive-agreement (6) · filing (6) · Pharmaceuticals (4) · equity-sale (4) · 10-Q (4) · corporate-action (3) · corporate-update (3) · pharmaceutical (3)

Key Numbers

Net Loss (Q3 2025): $1.569M — Improved from $2.365M in Q3 2024
Net Loss (9 Months 2025): $2.397M — Improved from $5.823M in 9 Months 2024
Product Sales, Net (Q3 2025): $4.952M — Increased from $4.496M in Q3 2024
Product Sales, Net (9 Months 2025): $10.622M — Decreased from $12.259M in 9 Months 2024
Gain on Contingent Royalty Liability: $1.933M — One-time accounting gain in Q3 2025
Accumulated Deficit: $900.176M — Increased from $897.664M at Dec 31, 2024
Total Stockholders' Deficit: $75.066M — Increased from $71.257M at Dec 31, 2024
Total Current Assets: $7.918M — Decreased from $13.609M at Dec 31, 2024
Total Current Liabilities: $78.186M — Slightly decreased from $80.448M at Dec 31, 2024
Common Stock Shares Outstanding: 126,685,925 — As of November 12, 2025
Common Stock Trading Price: $0.01 — As of the Record Date, necessitating a reverse stock split
Shares Issued and Outstanding: 126,685,925 — As of the Record Date
Reverse Stock Split Ratio Range: 1-for-500 and 1-for-1,500 — Proposed to meet Nasdaq listing standards
Target Year for EBITDA Positive: 2027 — Expected with appropriate growth capital and commercial strategy execution
PHEXX COGs Reduction Target: 55% — From current levels with a second manufacturer

Frequently Asked Questions

What are the latest SEC filings for Evofem Biosciences, INC. (EVFM)?

Evofem Biosciences, INC. has 44 recent SEC filings from Jan 2024 to Nov 2025, including 30 8-K, 6 10-Q, 2 DEFA14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of EVFM filings?

Across 44 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 37 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Evofem Biosciences, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Evofem Biosciences, INC. (EVFM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Evofem Biosciences, INC.?

Key financial highlights from Evofem Biosciences, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for EVFM?

The investment thesis for EVFM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Evofem Biosciences, INC.?

Key executives identified across Evofem Biosciences, INC.'s filings include Saundra Pelletier, Ivy Zhang.

What are the main risk factors for Evofem Biosciences, INC. stock?

Of EVFM's 36 assessed filings, 6 were flagged high-risk, 25 medium-risk, and 5 low-risk.

What are recent predictions and forward guidance from Evofem Biosciences, INC.?

Forward guidance and predictions for Evofem Biosciences, INC. are extracted from SEC filings as they are enriched.